Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CTMX CytomX Therapeutics	$2.52 +5.0%	$1.10	$0.40 ▼ $2.64	$203.17M	1.11	2.14 million shs	3.55 million shs
ELDN Eledon Pharmaceuticals	$3.09 -1.9%	$3.08	$2.30 ▼ $5.54	$185.04M	0.08	273,556 shs	217,225 shs
KOD Kodiak Sciences	$3.57 +2.0%	$3.31	$1.92 ▼ $11.60	$188.37M	2.42	345,668 shs	180,763 shs
XLO Xilio Therapeutics	$0.96 +2.9%	$0.77	$0.62 ▼ $1.70	$49.91M	-0.27	1.38 million shs	365,620 shs

10 Stocks Set to Soar in Spring 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CTMX CytomX Therapeutics	+5.00%	+18.31%	+286.74%	+272.12%	+44.00%
ELDN Eledon Pharmaceuticals	-1.90%	+2.32%	-5.50%	-25.54%	+28.75%
KOD Kodiak Sciences	+2.00%	+0.56%	-14.18%	-13.14%	+21.02%
XLO Xilio Therapeutics	+2.88%	+7.46%	+27.52%	+6.39%	+2.98%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CTMX CytomX Therapeutics	4.4234 of 5 stars	3.5	2.0	4.7	3.2	2.5	1.3
ELDN Eledon Pharmaceuticals	2.7752 of 5 stars	3.5	4.0	0.0	3.6	1.7	0.0
KOD Kodiak Sciences	4.1021 of 5 stars	3.0	3.0	4.6	1.8	3.3	0.6
XLO Xilio Therapeutics	2.359 of 5 stars	3.5	2.0	0.0	2.4	0.8	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CTMX CytomX Therapeutics	3.00	Buy	$5.33	111.64% Upside
ELDN Eledon Pharmaceuticals	3.00	Buy	$12.50	304.53% Upside
KOD Kodiak Sciences	2.00	Hold	$9.00	152.10% Upside
XLO Xilio Therapeutics	3.00	Buy	$4.00	314.98% Upside

Current Analyst Ratings Breakdown

Latest XLO, ELDN, KOD, and CTMX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/15/2025	CTMX CytomX Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$2.50 ➝ $5.00
5/15/2025	CTMX CytomX Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$5.00 ➝ $5.00
5/12/2025	CTMX CytomX Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$5.00 ➝ $6.00
4/14/2025	CTMX CytomX Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight ➝ Overweight	$3.25 ➝ $2.50
3/31/2025	KOD Kodiak Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$3.00 ➝ $3.00
3/7/2025	CTMX CytomX Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$5.00
3/7/2025	CTMX CytomX Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral

(Data available from 5/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CTMX CytomX Therapeutics	$147.56M	1.38	N/A	N/A	($0.71) per share	-3.55
ELDN Eledon Pharmaceuticals	N/A	N/A	N/A	N/A	$0.30 per share	N/A
KOD Kodiak Sciences	N/A	N/A	N/A	N/A	$5.07 per share	N/A
XLO Xilio Therapeutics	$9.27M	5.38	N/A	N/A	$1.34 per share	0.72

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CTMX CytomX Therapeutics	-$570K	$0.48	14.82	N/A	N/A	10.96%	-41.47%	8.11%	8/14/2025 (Estimated)
ELDN Eledon Pharmaceuticals	-$116.54M	-$2.10	N/A	N/A	N/A	N/A	-189.99%	-28.17%	8/18/2025 (Estimated)
KOD Kodiak Sciences	-$260.49M	-$3.63	N/A	N/A	N/A	N/A	-84.52%	-45.40%	8/13/2025 (Estimated)
XLO Xilio Therapeutics	-$76.40M	-$0.84	N/A	N/A	N/A	N/A	-211.50%	-80.31%	8/14/2025 (Estimated)

Latest XLO, ELDN, KOD, and CTMX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	ELDN Eledon Pharmaceuticals	-$0.28	-$0.08	+$0.20	-$0.08	N/A	N/A
5/14/2025	Q1 2025	KOD Kodiak Sciences	-$0.89	-$1.09	-$0.20	-$1.09	N/A	N/A
5/13/2025	Q1 2025	XLO Xilio Therapeutics	$0.10	-$0.18	-$0.28	-$0.18	$42.00 million	$2.93 million
5/12/2025	Q1 2025	CTMX CytomX Therapeutics	$0.18	$0.27	+$0.09	$0.27	$35.42 million	$50.92 million
3/27/2025	Q4 2024	KOD Kodiak Sciences	-$0.90	-$0.84	+$0.06	-$0.84	N/A	N/A
3/20/2025	Q4 2024	ELDN Eledon Pharmaceuticals	-$0.32	-$0.64	-$0.32	-$0.64	N/A	N/A
3/11/2025	Q4 2024	XLO Xilio Therapeutics	-$0.22	-$0.20	+$0.02	-$0.20	$2.26 million	$1.72 million
3/6/2025	Q4 2024	CTMX CytomX Therapeutics	-$0.23	$0.22	+$0.45	$0.22	$13.53 million	$38.09 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CTMX CytomX Therapeutics	N/A	N/A	N/A	N/A	N/A
ELDN Eledon Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
KOD Kodiak Sciences	N/A	N/A	N/A	N/A	N/A
XLO Xilio Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CTMX CytomX Therapeutics	N/A	1.04	1.04
ELDN Eledon Pharmaceuticals	N/A	6.53	6.53
KOD Kodiak Sciences	N/A	8.42	8.42
XLO Xilio Therapeutics	N/A	1.67	1.67

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CTMX CytomX Therapeutics	67.77%
ELDN Eledon Pharmaceuticals	56.77%
KOD Kodiak Sciences	89.06%
XLO Xilio Therapeutics	54.29%

Insider Ownership

Company	Insider Ownership
CTMX CytomX Therapeutics	7.00%
ELDN Eledon Pharmaceuticals	12.30%
KOD Kodiak Sciences	45.30%
XLO Xilio Therapeutics	5.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CTMX CytomX Therapeutics	170	80.62 million	72.78 million	Optionable
ELDN Eledon Pharmaceuticals	10	59.88 million	52.75 million	Optionable
KOD Kodiak Sciences	90	52.76 million	28.79 million	Optionable
XLO Xilio Therapeutics	70	51.78 million	41.67 million	Not Optionable

XLO, ELDN, KOD, and CTMX Headlines

Recent News About These Companies

Xilio Therapeutics, Inc. (NASDAQ:XLO) Sees Large Growth in Short Interest

May 30 at 1:27 AM | americanbankingnews.com

Xilio Therapeutics (NASDAQ:XLO) Upgraded by Wall Street Zen to "Buy" Rating

May 23, 2025 | americanbankingnews.com

Xilio Therapeutics, Inc.: Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2025 Financial Results

May 8, 2025 | finanznachrichten.de

Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2025 Financial Results

May 8, 2025 | finance.yahoo.com

Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2025 Financial Results

May 8, 2025 | globenewswire.com

Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

May 2, 2025 | globenewswire.com

Xilio Therapeutics to Present Updated Phase 2 Data for Vilastobart, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Combination with Atezolizumab in Patients with Microsatellite Stable Colorectal Cancer at the 2025 ASCO Annual Meeting

April 23, 2025 | globenewswire.com

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 4, 2025 | globenewswire.com

Xilio Therapeutics reports Q4 EPS (20c) vs (64c) last year

March 11, 2025 | markets.businessinsider.com

Xilio Therapeutics files $250M mixed securities shelf

March 11, 2025 | markets.businessinsider.com

Xilio Therapeutics, Inc. (XLO) Reports Q4 Loss, Lags Revenue Estimates

March 11, 2025 | zacks.com

Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2024 Financial Results

March 11, 2025 | globenewswire.com

Xilio Therapeutics to Present at TD Cowen 45th Annual Health Care Conference

February 24, 2025 | globenewswire.com

Xilio Therapeutics, Inc.: Xilio Therapeutics Announces Multiple Masked T Cell Engager Programs

February 12, 2025 | finanznachrichten.de

Xilio Therapeutics Shares Surge Premarket on AbbVie Deal

February 12, 2025 | marketwatch.com

AbbVie, Xilio Hook up

February 12, 2025 | baystreet.ca

AbbVie signs heavily backloaded $2.1B Xilio biobucks pact in Big Pharma's latest T-cell engager deal

February 12, 2025 | fiercebiotech.com

AbbVie expands oncology R&D with Xilio deal

February 12, 2025 | thepharmaletter.com

Xilio Therapeutics Announces Multiple Masked T Cell Engager Programs

February 12, 2025 | globenewswire.com

AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies

February 12, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

XLO, ELDN, KOD, and CTMX Company Descriptions

CytomX Therapeutics NASDAQ:CTMX

$2.52 +0.12 (+5.00%)

Closing price 05/29/2025 04:00 PM Eastern

Extended Trading

$2.50 -0.02 (-0.63%)

As of 05/29/2025 07:59 PM Eastern

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

Eledon Pharmaceuticals NASDAQ:ELDN

$3.09 -0.06 (-1.90%)

Closing price 05/29/2025 04:00 PM Eastern

Extended Trading

$3.10 +0.01 (+0.16%)

As of 05/29/2025 06:09 PM Eastern

Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.

Kodiak Sciences NASDAQ:KOD

$3.57 +0.07 (+2.00%)

Closing price 05/29/2025 04:00 PM Eastern

Extended Trading

$3.54 -0.03 (-0.84%)

As of 05/29/2025 06:09 PM Eastern

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

Xilio Therapeutics NASDAQ:XLO

$0.96 +0.03 (+2.88%)

Closing price 05/29/2025 04:00 PM Eastern

Extended Trading

$1.04 +0.08 (+7.90%)

As of 05/29/2025 08:00 PM Eastern

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time